LONDON (Reuters) – Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S. start-up Rani Therapeutics on a “robotic pill” for complex biotech drugs that would normally have to be given by injection.
Rani said it would run feasibility studies over the next 18-24 months to evaluate how selected Novartis biologic medicines can be delivered into the bloodstream using its unique device.
LONDON, May 26 (Reuters) – AstraZeneca’s hopes of
topping $45 billion in revenue by 2023 have been dealt a blow by
a problem with an experimental psoriasis drug that the drugmaker
had viewed as a potential billion-dollar plus seller.
Amgen, its partner on the project, announced late
on Friday it was ending a collaboration to develop brodalumab
after suicidal thoughts were observed in patients taking the
LONDON, May 26 (Reuters) – The life sciences industry is
increasingly taking over from the tech sector in driving global
innovation, according to a Thomson Reuters analysis of global
With more patents applied for or granted in 2014 than in any
other year in history, humankind has never been more inventive,
whether in designing driverless cars, discovering new drugs for
cancer or building bionic limbs.
LONDON, May 19 (Reuters) – Amgen’s new cholesterol
drug Repatha could be recommended for approval in Europe as
early as this week, putting it ahead in a race with a rival
product from Sanofi.
Repatha, or evolocumab, belongs to a new class of
cholesterol-lowering drugs known as PCSK9 inhibitors that
clinical trials suggest may slash the risks of heart attacks
compared to standard treatment alone.
LONDON, May 19 (Reuters) – In a central London pub, a young
bearded physicist is demonstrating how to build a model of the
universe from plastic Lego bricks. Clue: you need a lot of them.
Across town, in different bars, other experts are probing
the mysteries of cancer and dementia, life on other planets, and
how to win a Nobel prize.
(Reuters) – A closely watched immune system-boosting drug cocktail from Britain’s AstraZeneca shows promise in advanced lung cancer, despite adverse side effects in a number of patients.
Researchers said on Wednesday that the combination of the experimental drugs MEDI4736 and tremelimumab had “a manageable safety profile with evidence of clinical activity, including in PD-L1 negative disease”.
LONDON (Reuters) – AstraZeneca is diving deeper into personalized healthcare with two projects that move the concept beyond cancer into respiratory disorders and heart disease.
Personalized or precision medicine, which tailors treatment to a patient’s genetic profile, is an increasing focus for drug companies, especially after an initiative from U.S. President Barack Obama in January.
LONDON (Reuters) – Britain’s GlaxoSmithKline, which decided last week to retain rather than float off its HIV drugs business, is to collaborate with U.S. scientists in developing a cure for AIDS.
Until recently, many researchers were reluctant to even discuss the possibility of curing the disease caused by HIV, which infects 35 million people worldwide, since the obstacles seemed insurmountable.
LONDON, May 7 (Reuters) – GlaxoSmithKline’s new
chairman Philip Hampton has thrown his support behind the
company’s current structure and chief executive despite pressure
from some shareholders for a change.
In his first comments since becoming chairman at the
conclusion of the drugmaker’s annual meeting on Thursday,
Hampton told reporters he hoped that CEO Andrew Witty would
continue to run GSK for a good length of time.
LONDON (Reuters) – GlaxoSmithKline (GSK.L: Quote, Profile, Research, Stock Buzz) laid out growth targets for its biggest businesses on Wednesday, hoping to convince investors that focusing on consumer health and vaccines would return the drugmaker to long-term growth.
It also scrapped plans to float its HIV drug business ViiV Healthcare, citing its strong outlook, and promised to pay a steady dividend of 80 pence a share over the next three years.